title: [Pharma-clinics. The drug of the month. Nevirapine. Viramune].
abstract: Nevirapine is the first non nucleoside reverse transcriptase inhibitor registered in Belgium and indicated in the treatment of HIV-1 infection. In association with 2 nucleoside analogues, its efficiency is similar to a tritherapy with protease inhibitor, particularly in naive patients with low viral load. It has a good tolerance profile and is easy to take. Studies in progress should permit to widen its indications.
authors.affiliation: Service de Médecine interne-Infectiologie, Université de Liège.
authors.forename: D
authors.initials: D
authors.lastname: Nkoghe
authors.forename: P
authors.initials: P
authors.lastname: Léonard
authors.forename: M
authors.initials: M
authors.lastname: Moutschen
authors.forename: J
authors.initials: J
authors.lastname: Demonty
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019829:Nevirapine / Q000494:pharmacology* / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine